Unraveling the anti-inflammatory effects of Mediterranean diet in patients with cancer remission.

Cancer remission patients showed distinct clusters linking inflammatory status, clinical variables, and metabolic profiles at baseline, without clear separation among cancer types.

• A total of 132 patients with cancer remission were enrolled in this observational pilot study.
• Anamnestic, anthropometric, bioimpedential, clinical, and nutritional data were collected at baseline.
• Serum concentrations of cytokines, chemokines, growth factors, and metabolic markers were measured.
• Baseline clustering confirmed associations between systemic inflammation and body composition features across different cancer types.

Leptin and Insulin levels decreased significantly after the Mediterranean diet intervention, particularly in Breast cancer patients.

• The dietary intervention was personalized and followed over a six-month period.
• Reductions in Leptin and Insulin were observed after the six-month follow-up.
• The effect was particularly pronounced in Breast cancer patients.
• These metabolic changes occurred alongside the dietary intervention targeting Mediterranean diet adherence.

Colorectal cancer patients exhibited reductions in pro-inflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α after the dietary intervention, even without weight loss or bioimpedential feature changes.

• The reduction in pro-inflammatory cytokines was observed at the six-month follow-up.
• The specific cytokines reduced included IL-1β, IL-6, IL-8, and TNF-α.
• These reductions occurred in the absence of weight loss and changes in bioimpedential features.
• This finding suggests a direct anti-inflammatory effect of the Mediterranean diet independent of body composition changes in Colorectal cancer patients.

Retrospective analysis revealed that nutritionally modified molecules were associated with metabolic and inflammatory risk factors at baseline.

• The retrospective analysis linked molecules altered by the dietary intervention back to baseline risk profiles.
• Associations were found between these molecules and both metabolic and inflammatory risk factors.
• This finding supports a mechanistic connection between dietary modulation and pre-existing inflammatory/metabolic status.

Low-grade chronic inflammation plays a crucial role in both cancer progression and cardiometabolic diseases, and cancer survivors display impaired quality of life and increased risk of cardiometabolic comorbidities.

• The study enrolled patients specifically in cancer remission to examine post-treatment inflammatory and metabolic burden.
• LGCI (low-grade chronic inflammation) was identified as a key mechanism connecting cancer and cardiometabolic risk.
• The Mediterranean Diet is widely recognized for beneficial effects on body composition and systemic inflammation, but direct evidence in cancer survivors was described as limited prior to this study.

The study had notable limitations including lack of a control group and a high attrition rate, characterizing it as an observational pilot study.

• No control group was included in the study design.
• High attrition rate was acknowledged as a limitation.
• The study was described as an 'observational pilot study.'
• Despite these limitations, the authors concluded that the evidence supports nutritional intervention as a 'promising complementary strategy in oncological management.'